ASIT biotech (Paris:ASIT) (BSE:ASIT) (ASIT - BE0974289218), a
Belgian clinical-stage biopharmaceutical company focused on the
research, development and future commercialization of breakthrough
immunotherapy products for the treatment of allergies, informs the
financial community that, due to administrative reasons, the publication
of its annual financial report (regulated information) has been pushed
back from April 21, 2017 to April 25, 2017.
About ASIT biotech
ASIT Biotech is a Belgian clinical stage biopharmaceutical company
focused on the development and future commercialization of a range of
breakthrough immunotherapy products for the treatment of allergies.
Thanks to its innovative ASIT+TM technology platform, ASIT biotech is
currently the only developer of AIT product candidates consisting of a
unique mixture of highly purified natural allergen fragments in an
optimal size selection. This innovation results in a short treatment,
expected to improve patient compliance and real-life effectiveness. ASIT
biotech’s product pipeline entails two novel ASIT+™ product candidates
targeting respiratory allergy with the highest prevalence (i.e. grass
pollen: gp-ASIT+TM and house dust mite: hdm-ASIT+TM), that could
significantly expand the current immunotherapy market. The Company
believes that its innovative ASIT+™ platform is flexible and would be
applicable across a range of allergies.
ASIT biotech has a headcount of 22 staff members, at its headquarters in
Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
All statements in this announcement that do not relate to historical
facts and events are "forward-looking statements”. In some cases, these
forward-looking statements can be identified by the use of
forward-looking terminology, including the words "believes,”
"estimates,” "anticipates,” "expects,” "intends,” "may,” "will,”
"plans,” "continue,” "ongoing,” "potential,” "predict,” "project,”
"target,” "seek” or "should” or, in each case, their negative or other
variations or comparable terminology or by discussions of strategies,
plans, objectives, targets, goals, future events or intentions.
Forward-looking statements include statements regarding the Company’s
intentions, beliefs or current expectations. By their nature,
forward-looking statements involve known and unknown risks and
uncertainties because they relate to events and depend on circumstances
that may or may not occur in the future. Forward-looking statements are
not guarantees of future performance. Given these risks and
uncertainties, you should not rely on forward-looking statements as a
prediction of actual results. Any forward-looking statements are made
only as of the date of this announcement and, without prejudice to the
Company’s obligations under applicable law in relation to disclosure and
ongoing information, the Company does not intend, and does not assume
any obligation, to update the forward-looking statements set forth in
This announcement does not constitute, or form part of, an offer or
invitation to sell or issue, or any solicitation of an offer to purchase
or subscribe for shares of ASIT biotech SA (the "Company” and the
"Shares”). Any purchase of, subscription for or application for, Shares
to be issued in connection with the intended offering should only be
made on the basis of information contained in the prospectus and any
supplements thereto, as the case may be. This announcement does not
constitute a prospectus and the information contained herein is for
information purposes only and does not purport to be full or complete.
Investors should not subscribe for any Shares except on the basis of the
information contained in the prospectus that the Company expects to
publish after its approval by the Belgian Financial Services and Markets
Authority, and which can then be obtained at the Company’s registered
office and on www.asitbiotech.com.
This announcement is not for distribution, directly or indirectly, in or
into the United States or to any U.S. person within the meaning of the
U.S. Securities Act of 1933, as amended (the "Securities Act”). The
Shares have not been and will not be registered under the Securities Act
and may not be offered or sold in the United States, except pursuant to
an exemption from the registration requirements of the Securities Act.
The Company has not registered, and does not intend to register, any
portion of the intended offering of Shares in the United States, and
does not intend to conduct a public offering of Shares in the United
This announcement and the information contained herein are not for
publication, distribution or release in or into the United States,
Australia, Canada, Japan or any jurisdiction where to do so would
constitute a violation of the relevant laws of such jurisdiction.
The Company is responsible for the information contained in this press
View source version on businesswire.com: http://www.businesswire.com/news/home/20170421005665/en/